Literature DB >> 31286393

Lack of association between functional polymorphism of DNA repair genes (XRCC1, XPD) and clinical response in Indian chronic myeloid leukemia patients.

Somprakash Dhangar1, Vinay Shanbhag1, Chandrakala Shanmukhaiah2, Babu Rao Vundinti3.   

Abstract

The resistance for the tyrosine kinase inhibitors in chronic myeloid leukemia (CML) occurs mainly due to BCR/ABL1 dependent and independent mechanisms. The defective DNA repair due to functional polymorphisms in DNA repair genes, might act as an etiological factor for leukemia progression. The study was carried out to understand the role of DNA repair genes (XRCC1, XPD) polymorphisms in Imatinib mesylate (IM) resistant CML patients. The study was carried out in total 87 CML patients (43 nonresponders-cases and 44 responders) who were treated with Imatinib. The treatment and follow-up was done according to European LeukemiaNet guidelines. The genotyping of selected SNPs were studied using RFLP and confirmed with Sanger sequencing (20%). The statistical analysis was performed using online tools (Socscistatistics and GraphPad InStat software). In our study no significant association was inferred between genotypes of DNA repair genes (XRCC1; rs1799782, rs25487, and XPD; rs13181) and complete cytogenetic response as well as molecular response. However there might be a possibility of association between XRCC1 Arg399Gln genotype AA/GA and cytogenetic response though it is statistically insignificant (p > 0.05). Though none of the genotypes of the DNA repair genes showed association with IM response, near association between XRCC1Arg399Gln genotype and cytogenetic response observed in our study. Hence, large sample size should be studied to establish the association of SNPs of DNA repair genes and IM response. Our study is a novel and important to explain the role of DNA repair genes polymorphisms in IM resistance.

Entities:  

Keywords:  Chronic myeloid leukemia (CML); Clinical response; DNA repair genes; Double strand break (DSB); Imatinib mesylate; Single nucleotide polymorphisms (SNPs)

Mesh:

Substances:

Year:  2019        PMID: 31286393     DOI: 10.1007/s11033-019-04950-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  23 in total

1.  Polymorphisms in XRCC1, ERCC2, and ERCC3 DNA repair genes, CYP1A1 xenobiotic metabolism gene, and tobacco are associated with bladder cancer susceptibility in Tunisian population.

Authors:  Molka Feki-Tounsi; Rim Khlifi; Ibtihel Louati; Mohamed Fourati; Mohamed-Nabil Mhiri; Amel Hamza-Chaffai; Ahmed Rebai
Journal:  Environ Sci Pollut Res Int       Date:  2017-08-12       Impact factor: 4.223

2.  Domain specific interaction in the XRCC1-DNA polymerase beta complex.

Authors:  A Marintchev; A Robertson; E K Dimitriadis; R Prasad; S H Wilson; G P Mullen
Journal:  Nucleic Acids Res       Date:  2000-05-15       Impact factor: 16.971

3.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

Authors:  Susan Branford; Zbigniew Rudzki; Sonya Walsh; Ian Parkinson; Andrew Grigg; Jeff Szer; Kerry Taylor; Richard Herrmann; John F Seymour; Chris Arthur; David Joske; Kevin Lynch; Tim Hughes
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

4.  Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Authors:  Ji Wu; Feng Meng; Ling-Yuan Kong; Zhenghong Peng; Yunming Ying; William G Bornmann; Bryant G Darnay; Betty Lamothe; Hanshi Sun; Moshe Talpaz; Nicholas J Donato
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

5.  Lack of association of XRCC1 codon 399Gln polymorphism with chronic myelogenous leukemia.

Authors:  Ugur Deligezer; Ebru E Akisik; Nejat Dalay
Journal:  Anticancer Res       Date:  2007 Jul-Aug       Impact factor: 2.480

6.  Genetic Variations of DNA Repair Genes in Breast Cancer.

Authors:  Asuman Özgöz; Kuyaş Hekimler Öztürk; Ayşegül Yükseltürk; Hale Şamlı; Zuhal Başkan; Fadime Mutlu İçduygu; Mehmet Bacaksız
Journal:  Pathol Oncol Res       Date:  2017-10-05       Impact factor: 3.201

Review 7.  Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Hagop M Kantarjian; Jorge E Cortes
Journal:  Cancer Control       Date:  2009-04       Impact factor: 3.302

Review 8.  Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.

Authors:  Brady Stein; B Douglas Smith
Journal:  Clin Ther       Date:  2010-05       Impact factor: 3.393

9.  Relevance of DNA repair gene polymorphisms to gastric cancer risk and phenotype.

Authors:  Patricia Carrera-Lasfuentes; Angel Lanas; Luis Bujanda; Mark Strunk; Enrique Quintero; Santos Santolaria; Rafael Benito; Federico Sopeña; Elena Piazuelo; Concha Thomson; Angeles Pérez-Aisa; David Nicolás-Pérez; Elizabeth Hijona; Jesús Espinel; Rafael Campo; Marisa Manzano; Fernando Geijo; María Pellise; Manuel Zaballa; Ferrán González-Huix; Jorge Espinós; Llúcia Titó; Luis Barranco; Mauro D'Amato; María Asunción García-González
Journal:  Oncotarget       Date:  2017-05-30

Review 10.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.